AOR
Archives of Ophthalmological Research

The Archives of Ophthalmological Research aims to publish issues related to publish articles of the highest scientific and clinical value at an international level, and accepts articles on these topics. The target audience of the journal included specialists and physicians working in ophthalmology, and other health professionals interested in these fields.

eISSN: 3023-6479
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Evaluation of the efficacy, safety, patient comfort, and preference of the fixed combination of brinzolamide 1% / timolol 0.5% in patients with pseudoexfoliation glaucoma
Abstract
Aims: The efficacy and safety of the fixed combination of brinzolamide 1%/timolol 0.5% (BTFC) have previously been demonstrated in primary open-angle glaucoma (POAG). The aim of this study was to evaluate the efficacy, adverse effect profile, and patient preference of BTFC in patients with pseudoexfoliation glaucoma (PEG), whose treatment approach is similar to POAG but whose clinical management is more challenging for various reasons.
Methods: A total of 37 eyes of 27 patients followed with a diagnosis of PEG were retrospectively analyzed. Intraocular pressure (IOP) values during the previous treatment period, the untreated baseline period, and at 1, 3, and 6 months after initiation of BTFC were evaluated. In addition, the efficacy, adverse effects, and patient preference related to BTFC were assessed.
Results: BTFC achieved a significant reduction of 33.4%–37.2% in IOP compared with baseline in PEG patients (p<0.001), and this effect was sustained throughout the 6-month follow-up. The most frequently reported adverse effect associated with BTFC was burning–stinging sensation (77%). While 48.1% of patients rated BTFC as very good and 51.9% as good, 51.9% preferred BTFC, whereas 18.5% preferred their previous treatment.
Conclusion: The findings indicate that BTFC is an effective treatment option preferred by patients with PEG, owing to its comparable efficacy and adverse effect profile relative to other antiglaucomatous therapies.

Keywords : Pseudoexfoliation glaucoma, brinzolamide/timolol, primary open-angle glaucoma

Download Article


1. Ritch R, Schlötzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol. 2001;45(4):265-315. doi:10.1016/s0039-6257(00)00196-x
2. Konstas AG, Mantziris DA, Stewart WC. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol. 1997;115(2):182-185. doi:10.1001/archopht.1997.01100150184006
3. Galose MS, Elsaied HM, Macky TA, Fouad PH. Brinzolamide/timolol versus dorzolamide/timolol fixed combinations: a hospital-based, prospective, randomized study. Indian J Ophthalmol. 2016;64(2):127-131. doi:10.4103/0301-4738.179718
4. Yilmaz I. Efficacy of brinzolamide-timolol maleate fixed combination in patients with primary open-angle glaucoma. MN Oftalmoloji. 2013; 20(1):20-23.
5. Yüksel N, Gök M, Altıntaş O, Cağlar Y. Diurnal intraocular pressure efficacy of the timolol-brimonidine fixed combination and the timolol-dorzolamide fixed combination as a first choice therapy in patients with pseudoexfoliation glaucoma. Curr Eye Res. 2011;36(9):804-808. doi:10.3109/02713683.2011.584651
6. Eliacik M, Karaman Erdur S, Baltepe Altıok I, Gulkilik G, Aslan CA, Kaya F. Effects of dorzolamide/timolol fixed combination on retrobulbar hemodynamics in pseudoexfoliative glaucoma. Kaohsiung J Med Sci. 2016;32(1):38-43. doi:10.1016/j.kjms.2015.12.004
7. Nebbioso M, Evangelista M, Librando A, Di Blasio D, Pescosolido N. Fixed topical combinations in glaucomatous patients and ocular discomfort. Expert Opin Pharmacother. 2012;13(13):1829-1835. doi:10.1517/14656566. 2012.705830
8. Rossi GCM, Pasinetti GM, Sandolo F, Bordin M, Bianchi PE. From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch study. Expert Opin Pharmacother. 2011;12(16):2425-2431. doi:10.1517/14656566.2011.589384
9. Nagayama M, Nakajima T, Ono J. Safety and efficacy of a fixed versus unfixed brinzolamide/timolol combination in Japanese patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2014;8: 219-228. doi:10.2147/OPTH.S55590
10. Lanzl I, Raber T. Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice. Clin Ophthalmol. 2011;5:291-298. doi:10.2147/OPTH.S16355
11. Croxtall JD, Scott LJ. Brinzolamide/timolol: in open-angle glaucoma and ocular hypertension. Drugs Aging. 2009;26(5):437-446. doi:10.2165/ 00002512-200926050-00007
12. Sezgin Akçay Bİ, Güney E, Bozkurt KT, Unlü C, Akçali G. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2013;29(10):882-886. doi: 10.1089/jop.2013.0102
13. Inoue K, Shiokawa M, Ishida K, Tomita G. Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops. Clin Ophthalmol. 2015;9:619-623. doi:10.2147/OPTH.S79843
14. Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2009;18(4):293-300. doi:10.1097/IJG.0b013e31818fb434
15. Vold SD, Evans RM, Stewart RH, Walters T, Mallick S. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2008;24(6):601-605. doi: 10.1089/jop.2008.0030
16. Mundorf TK, Rauchman SH, Williams RD, Notivol R, Brinzolamide/Timolol Preference Study Group. A patient preference comparison of Azarga (brinzolamide/timolol fixed combination) vs Cosopt (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2008;2(3):623-628. doi:10.2147/opth.s4088
17. Sanseau A, Sampaolesi J, Suzuki ER, Lopes JF, Borel H. Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/timolol among patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2013;7:357-362. doi:10.2147/OPTH.S38575
18. Altafini R, Scherzer ML, Hubatsch D, Frezzotti P. Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study. Clin Ophthalmol. 2015;9:2263-2270. doi:10.2147/OPTH.S88891
19. Beckers H. Schouten JS, Webers CA. Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2009;3:593-599. doi:10.2147/opth.s4853
20. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23(5):490-496. doi:10.1097/01.ico.0000116526.57227.82
Article available in :
Volume 3, Issue 1, 2026
Page : 1-5
https://doi.org/10.51271/AOR-0044
Article Information
Received : 14 Oca 2026
Accepted : 24 Şub 2026
Published : 19 Mar 2026
Corresponding Author :

Hatice Ergün: Department of Ophthalmology, Kayseri City Hospital, Kayseri, Turkiye

[email protected]
Citation : Ergün H, Kemer ÖE. Evaluation of the efficacy, safety, patient comfort, and preference of the fixed combination of brinzolamide 1%/timolol 0.5% in patients with pseudoexfoliation glaucoma. Arch Ophthalmol Res. 2026;3(1):1-5. doi:10.51271/AOR-0044

Read: 91
Download : 48
Cited: 0
_Footer